Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.

Authors :: Nissen NI
Hansen HH
Pedersen H
Stroyer I
Dombernowsky P
Hessellund M
Source :: Cancer chemotherapy reports [Cancer Chemother Rep] 1975 Sep-Oct; Vol. 59 (5), pp. 1027-9.
Publication Year :: 1975

Subjects :: Administration, Oral
Alopecia chemically induced
Clinical Trials as Topic
Drug Evaluation
Etoposide administration & dosage
Etoposide adverse effects
Gastrointestinal Diseases chemically induced
Hematologic Diseases chemically induced
Humans
Etoposide therapeutic use
Neoplasms drug therapy
Podophyllotoxin therapeutic use

Tools